Somnus Technologies terracotta orb mark SOMNUS TECHNOLOGIES

Somnus Technologies™

We are building
honest nightstand sensing for how you
breathe.

Nightsong™ + BSA™ turn a phone on the nightstand into on-device snore-burden and breathing-regularity reads — then the Somnus Index™, a you-vs-you wellness number. Optional richer sense next: Bedside Node™.

Modern AI. Kept honest. On your phone.

Book a call

Somnus leads with Nightsong + BSA — honest nightstand sensing for how you breathe.

On-device snore-burden and breathing-regularity reads, a you-vs-you Index only when the night was heard, and optional richer sense next — without claiming diagnosis.

84M1

American adults have obstructive sleep apnea.
About 80% don't know it.2

54 million by the most conservative widely-cited estimate.4

  • Roughly 8 in 10 remain undiagnosed2
  • 34.1% CPAP non-adherence (7-hours-per-night criterion)3

Snoring is the most common early sign of OSA. 26.4% of US adults snore 5+ nights a week, about 71 million people (Derived).5

Why do so many people never get a clear read on their own nights?

Most tools stop at a fragment. We start with something you already own.

On-device acoustic sensing (Nightsong + BSA), an honest Index when the night was heard, and a path to richer bedside sense — without claiming diagnosis.

Epidemiology below is context for how common snoring and sleep-breathing struggle are. It is not our product pitch, and it is not a diagnostic claim.

The opportunity

Sleep is the largest un-instrumented lever in longevity, and airway dysfunction is where it breaks first.

How does the Somnus closed-loop system work?

Six stages. One connected system. Built to keep improving over time.

We are building the loop.

AI-powered insight across every step of the loop.

Nightsong + BSA Acoustic · any phone SENSOR future Agent All nodes SENSOR Bedside Node SENSOR Therapy Outcomes Post-procedure data FEEDBACK Provider Directory™ HYPNARA™ Implant THERAPY MORPHEX™AI THERAPY Other Competing therapies CPAP · HGNS · OTHER

SOMNUS INDEX · THE HUB

  1. Sense

    Nightsong + BSA turn any phone on the nightstand into an on-device acoustic sensor. Bedside Node is optional richer sense next. MORPHEX AI is a future mark — not for sale.

  2. Score

    The Somnus Index is you-vs-you wellness: snore burden and breathing regularity over your own nights. No Index if the night was not heard.‡

  3. Route

    A wellness directory and roadmap routing — not an implant funnel.

  4. Therapy

    Future therapy marks (MORPHEX AI, HYPNARA) — not cleared, not for sale — and not the focus of what we are shipping now.

  5. Outcomes

    Index nights that were actually heard, plus adherence and experience over time — framed around honest sensing, not post-implant only.

  6. Re-score

    Heard nights feed back into your own baseline, so the Index stays honest over time.

Built for the long term.

What does Somnus build?

Shipping first: Nightsong + BSA. Next sense: Bedside Node. Therapy marks are future, not for sale.

SHIPPING FIRST · ENROLLING NOW

Nightsong + the Somnus Index

Your phone on the nightstand becomes the sensor. No wearable, no hardware, nothing to buy.

On-device when the night is heard. BSA runs on your phone. If the night wasn’t heard clearly enough, we don’t invent an Index — no fake score to fill the gap. When we do score, the Somnus Index is you vs you: snore burden and breathing regularity over your own nights, wellness only.

Your data is your data. The analysis happens on the phone in your hand. Your recordings stay on your device, and you decide if anything is ever shared.

Built to the FDA's General Wellness policy. A low-risk tool to understand your sleep. Not a medical device, and not a diagnosis.

Targeting · Fall 2026
The Nightsong Home screen in the morning: a Somnus Index of 73 labeled Steady, the line A steady night, in your typical range, above cards for breathing, snore and sleep.
The Nightsong Apple Watch screen: a Somnus Index of 84 labeled Steady, right around your recent nights.
NEXT SENSE · ROADMAP

Bedside Node

Optional richer sense at the bedside — a next hardware node on the sense track, not a requirement to start. Roadmap.

Roadmap sense node. Not required to begin with Nightsong + BSA.

FUTURE · NOT FOR SALE

MORPHEX AI

A future smart oral-device concept with on-device analytics. Not the focus of what we are shipping now. Not for sale.

Not yet available. Not FDA cleared. Not for sale.

FUTURE · NOT CLEARED / NOT FOR SALE

HYPNARA

A future therapy concept on the Somnus long arc — a passive structural palatal implant. Not the public product focus.

Not yet FDA cleared. Not for sale. Pre-Submission complete May 7, 2026.

Network

Somnus Provider Directory

A patient-browsable directory of sleep-health providers sourced from public registry data. Neutral and informational: no credentialing claim, wellness context. The routing intelligence layer is a roadmap capability.

Intellectual Property

Multiple patent-pending applications across the platform.

We pay attention to what happens after therapy, not just before it.

How does Somnus navigate regulatory risk?

Software side: de-risked

Counsel review concludes the Nightsong app, the BSA acoustic engine, and the Somnus Index fit within the FDA General Wellness Policy.

"FDA-classification de-risked on the software side" is the lead de-risking headline.

Therapy marks: future

Future therapy concepts (HYPNARA and related hardware) sit on a deliberate FDA pathway. They are not cleared and not for sale — and not what we lead with on this site. Details live on Med-Device and HYPNARA.

This is who we are.

We’re shipping honest nightstand sensing first — Nightsong + BSA and an Index that only exists when the night was heard — then optional richer sense, then a longer network and therapy arc without implant-first proof claims on this public brand home. We intend to set the standard for integrity: not the loudest, not a pretend score to keep a streak.

We respect expertise. We tell the truth about what’s built and what isn’t. We earn trust the slow way, because it’s the only way that holds.

You don’t have to agree with how we work. But if you do (if you want the best solution, done the right way), there’s a place for you here.

For clinics

Nightsong between visits

Design partner pilots and network licensing for ENT groups and sleep practices — a wellness instrument that runs when patients are home.

Explore licensing

For technology partners

Powered by BSA

BSA licensing and partnership is available for digital health, bedside devices, and the rest of the bedroom stack under your brand.

Partner with us

Ready to learn more?

Somnus Technologies is built for the long term: lean, close to patients and providers, owning the loop.

Book a call

1 Derived: US Census Vintage 2025 age bands with published age-specific prevalence (Benjafield 2019; Haas 2005; Bixler 1998 / Zasadzińska-Stempniak 2024).

2 Young et al., Sleep 1997;20:705 (Wisconsin Sleep Cohort, NIH-funded): an estimated 82% of men and 93% of women with moderate-to-severe sleep-disordered breathing were undiagnosed. Corroborated by Kapur et al., Sleep and Breathing 2002. 1990s cohort data; no modern national re-measurement exists.

3 Rotenberg et al., Journal of Otolaryngology, Head & Neck Surgery 2016. Systematic review of 82 papers over twenty years; 34.1% CPAP non-adherence at the 7-hours-per-night criterion.

4 Benjafield et al., Lancet Respiratory Medicine 2019 (ResMed-funded). Conservative estimate: 54 million US adults aged 30 to 69.

5 Derived: Somnus analysis of NHANES 2017 to March 2020 (CDC/NCHS), variable SLQ030, n=8,991 adults, survey-weighted.

‡ Somnus Index is a wellness metric under FDA General Wellness Policy. Not a medical device.